Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 6 NIH 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25 Leukemia, Myeloid, Chronic-Phase 14 Leukemia 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Recurrence 4 Breast Neoplasms 4 Blast Crisis 4 Prostatic Neoplasms 3 Neoplasms 3 Bronchiolitis Obliterans Syndrome 3 Neoplasm Metastasis 2 Multiple Myeloma 2 Leukemia, Myeloid, Acute 2 Leukemia, Myeloid, Accelerated Phase 2 Advanced Breast Cancer 2 Philadelphia Chromosome 1 Pancreatic Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Indications Cancer 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Cancer 1

Interventions

Gemcitabine 205 130-nm albumin-bound paclitaxel 84 Albumin-Bound Paclitaxel 57 pembrolizumab 43 Fluorouracil 41 Leucovorin 34 Oxaliplatin 33 Capecitabine 25 Nivolumab 22 Irinotecan 19 Bevacizumab 17 Paclitaxel 16 Cyclophosphamide 15 Cetuximab 15 Taxes 13 Erlotinib Hydrochloride 13 Drug Therapy 13 Carboplatin 12 irinotecan sucrosofate 11 Injections 10 Cisplatin 9 fludarabine 8 ALT-803 8 spartalizumab 7 olaparib 7 avelumab 7 Pemetrexed 7 Docetaxel 7 ruxolitinib 6 TH 302 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pancreatic Neoplasms × Dasatinib × Clear all

NCT01395017 2016-04-08

LAPC

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2 Completed

202 enrolled 9 charts

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡